Benjamin Besse, MD, PhD, shares AE management strategies for amivantamab/lazertinib in EGFR-positive NSCLC following CHRYSALIS-2 results.
Benjamin Besse, MD, PhD
Advertisement
Benjamin Besse, MD, PhD, is the director of Clinical research at Gustave Roussy.
Articles by Benjamin Besse, MD, PhD
Advertisement
Latest Updated Articles
Safety Management With Amivantamab Plus Lazertinib in NSCLCSeptember 11th 2025
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Managing Rash and Stomatitis With Daraxonrasib in Pancreatic Cancer
2
FDA Approves Oral Nilotinib Tablets for Ph+ CML
3
Nursing Guide to Managing Lorlatinib in ALK+ NSCLC: 7-Year CROWN Insights
4
GLP-1 RAs Linked to Lower HR+ Breast Cancer Risk and Improved Survival
5